Cargando…

Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with Denosumab

SIMPLE SUMMARY: Denosumab, a bone-modifying agent, has been approved for the prevention of or reduction in skeletal-related events (SREs) in non-small cell lung cancer (NSCLC) patients with bone metastasis. However, the effect of denosumab on survival of epidermal growth factor receptor (EGFR)-mutat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ko, How-Wen, Chiu, Chi-Tsun, Wang, Chih-Liang, Yang, Tsung-Ying, Liu, Chien-Ying, Yu, Chih-Teng, Tseng, Li-Chuan, Kuo, Chih-Hsi Scott, Wang, Chin-Chou, Yang, Muh-Hwa, Yang, Cheng-Ta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316991/ https://www.ncbi.nlm.nih.gov/pubmed/35884531 http://dx.doi.org/10.3390/cancers14143470

Ejemplares similares

Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation
por: Ko, How-Wen, et al.
Publicado: (2022)

The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations
por: Liu, Chien-Ying, et al.
Publicado: (2017)

A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy
por: Wang, Chin-Chou, et al.
Publicado: (2021)

Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions
por: Hsu, Ping-Chih, et al.
Publicado: (2016)

Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR‐mutant and EGFR‐wild type nonsquamous non‐small cell lung cancer
por: Huang, Yu‐Chen, et al.
Publicado: (2018)

Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non‐small cell lung cancer
por: Kuo, Chih‐Hsi Scott, et al.
Publicado: (2019)

Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2015)

First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
por: Huang, Allen Chung-Cheng, et al.
Publicado: (2021)

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study
por: Lee, Suey-Haur, et al.
Publicado: (2022)

The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis
por: Chiu, Tzu-Hsuan, et al.
Publicado: (2022)

Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation
por: Kuo, Chih-Hsi Scott, et al.
Publicado: (2022)

Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2016)

A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial
por: Lee, Chia-Che, et al.
Publicado: (2021)

Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2015)

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status
por: Hsu, Chia-Hung, et al.
Publicado: (2016)

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer
por: Chu, Chia‐Hsun, et al.
Publicado: (2020)

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2016)

Comparison of the Effects of Denosumab and Alendronate on Cardiovascular and Renal Outcomes in Osteoporotic Patients
por: Hsu, Tsuen-Wei, et al.
Publicado: (2019)

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

No Mortality Difference Following Treatment with Terlipressin or Somatostatin in Cirrhotic Patients with Gastric Variceal Hemorrhage
por: Hung, Tsung-Hsing, et al.
Publicado: (2016)

Safety range of free valproic acid serum concentration in adult patients
por: Tseng, Yu-Ju, et al.
Publicado: (2020)

High mortality of pneumonia in cirrhotic patients with ascites
por: Hung, Tsung-Hsing, et al.
Publicado: (2013)

Effect of Renal Function Impairment on the Mortality of Cirrhotic Patients With Hepatic Encephalopathy: A Population-Based 3-Year Follow-Up Study
por: Hung, Tsung-Hsing, et al.
Publicado: (2014)

No difference in mortality between terlipressin and somatostatin treatments in cirrhotic patients with esophageal variceal bleeding and renal functional impairment
por: Hung, Tsung-Hsing, et al.
Publicado: (2016)

The Effect of the First Spontaneous Bacterial Peritonitis Event on the Mortality of Cirrhotic Patients with Ascites: A Nationwide Population-Based Study in Taiwan
por: Hung, Tsung-Hsing, et al.
Publicado: (2016)

The long-term outcomes of cirrhotic patients with pleural effusion
por: Hung, Tsung-Hsing, et al.
Publicado: (2018)

Endoscopic papillary balloon dilation decreases the risk of bleeding in cirrhotic patients compared with endoscopic biliary sphincterotomy: A national population-based study
por: Hung, Tsung-Hsing, et al.
Publicado: (2019)

Denosumab Attenuates Glucolipotoxicity-Induced β-Cell Dysfunction and Apoptosis by Attenuating RANK/RANKL Signals
por: Lin, Sheng-Chieh, et al.
Publicado: (2023)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

Association of Heavy Metals with Overall Mortality in a Taiwanese Population
por: Liu, Yi-Hsueh, et al.
Publicado: (2021)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Denosumab Is Superior to Raloxifene in Lowering Risks of Mortality and Ischemic Stroke in Osteoporotic Women
por: Liu, Ting-Chun, et al.
Publicado: (2023)

Hypoxia Inhibits Osteogenesis in Human Mesenchymal Stem Cells through Direct Regulation of RUNX2 by TWIST
por: Yang, Der-Chih, et al.
Publicado: (2011)

High Mortality of Cirrhotic Patients With End-Stage Renal Disease
por: Hung, Tsung-Hsing, et al.
Publicado: (2016)

Interval between Intra-Arterial Infusion Chemotherapy and Surgery for Locally Advanced Oral Squamous Cell Carcinoma: Impacts on Effectiveness of Chemotherapy and on Overall Survival
por: Wu, Chih-Fung, et al.
Publicado: (2014)

Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
por: Chiu, Li-Chung, et al.
Publicado: (2021)

Brain-derived neurotrophic factor (BDNF) -TrKB signaling modulates cancer-endothelial cells interaction and affects the outcomes of triple negative breast cancer
por: Tsai, Yi-Fang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qu9ju55orape5v4cdun042jusu